Emerging Treatment Updates: Antibody Drug Conjugates in Relapsed/Refractory Follicular Lymphoma : Episode 2
Exploring ADC/Antibody Combination Therapies in Development for R/R FL
A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with rituximab for R/R FL based on its complementary mechanism of action targeting CD19-expressing B -cells, demonstrated single-agent activity in early studies, and preliminary evidence suggesting potential synergy with anti-CD20 therapy in this setting.
Video content above is prompted by the following:
Next, provide context for combination loncastuximab plus+ rituximab in R/R FL.
- How can novel combinations that include antibody-drug conjugates (ADCs) impact the landscape?
- Introduce loncastuximab: target, MOA. What was the rationale for testing loncastuximab plus+ rituximab in R/R FL?
- Patients with FL patients from pPhase 1 loncastuximab in R/R B-NHL
- What additional preliminary evidence supports the combination in this setting?
Recent Videos
Related Content
